For decades, NORD has pursued federal and state policies that will change the lives of Americans impacted by rare diseases for the better. NORD’s work can be viewed below. This page is updated daily to provide timely information. Please contact us if you have questions or need additional information.
NORD and 86 other organizations oppose the Senate including changes to the Orphan Drug Tax Credit in the Build Back Better Act
Published: Sep 21, 2021
Tagged in: Research, Access to Innovative Medicines and Therapies, Advancing Rare Disease Research and Regulatory Science, Orphan Drug Act, Orphan Drug Tax Credit
NORD and 86 other organizations ask for the removal of provisions related to the Orphan Drug Tax Credit in the House version of the Build Back Better Act
Published: Sep 21, 2021
Tagged in: Research, Access to Innovative Medicines and Therapies, Advancing Rare Disease Research and Regulatory Science, Orphan Drug Act, Orphan Drug Tax Credit
NORD letter to House Ways & Means Committee opposing Section 138141 of the Build Back Better Act
Published: Sep 13, 2021
Tagged in: Access to Innovative Medicines and Therapies, Orphan Drug Act, Orphan Drug Tax Credit
NORD submits comments on FDA Draft Guidance on Interpreting Sameness for Gene Therapy Products Under the Orphan Drug Regulations
Published: Jul 28, 2020
Tagged in: Gene Therapies, Advancing Rare Disease Research and Regulatory Science, Orphan Drug Act
NORD comments to FDA regarding its definition of low-prevalence in a recent draft guidance
Published: Sep 25, 2018
Tagged in: Access to Affordable Medicines, Access to Innovative Medicines and Therapies, Orphan Drug Act
NORD comments to the American Medical Association expressing concerns with their resolution proposing reforms to the ODA
Published: Jun 1, 2018
Tagged in: Access to Innovative Medicines and Therapies, Orphan Drug Act
